Latest Breaking News On - Namocell inc - Page 3 : comparemela.com
Bio-Techne (TECH) Acquires Namocell
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Worldwide Next-Generation Sequencing Industry to 2025 - Key Drivers and Trends
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted).
Liquid biopsy is creating a paradigm shift in medicine, and this is opening significant market opportunities. These market segments are particularly promising for the following liquid biopsy applications: noninvasive prenatal screening for average-risk populations; cancer screening and early detection; and recurrence monitoring for cancer patients.
Biomarker types of most interest include cell-free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes. Ongoing advances in sensitive molecular technologies such as next-generation DNA sequencing (NGS) and digital polymerase chain reaction (dPCR) enable the detection of biomarkers that are present
Share this article
Share this article
PALO ALTO, Calif., March 12, 2021 /PRNewswire/ HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. (TBUSA) announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like cells (iHeps) differentiated from adipose tissue-derived stromal cells (ASCs) using Namocell s Single Cell Dispensers and Takara Bio s SMART-seq® kits to characterize HepaTx s novel cell therapies for liver disease. The results of the second phase demonstrated a 95% success rate in single cell isolation and library construction. Single cell RNA-seq showed distinct clusters of cells at various differentiation stages. The high reproducibility of results within sample groups will support development of novel cell therapies and validate production processes.
Key Companies Profiled
$3,188.9 Million
Healthcare experts have found the single-cell multi-omics market to be one of the most rapidly evolving markets, which is predicted to grow at a CAGR of 21.16% during the forecast period, 2020-2025. The market is driven by the need for the development of an advanced solution based on single-cell technology for clinical research in various applications such as cancer, rare disease, cell biology, and synthetic biology, among others.
The market is favored by the development of single-cell technology-based solutions for visualization and analysis of cell heterogeneity, tumor microenvironment, and antibody development. The gradual increase in the prevalence of oncology and rare diseases globally has furthered the single-cell multi-omics market.
vimarsana © 2020. All Rights Reserved.